NASDAQ: MCTACharming Medical Ltd Stock
$29.36+0.00 (+0%)
Updated Nov 2, 2026
MCTA Price
$29.36
Fair Value Price
$1.65
Market Cap
$504.26M
52 Week Low
$19.01
52 Week High
$31.70
P/E
N/A
P/B
97.33x
P/S
98.61x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.81M
Earnings
-$22.65k
Gross Margin
65.5%
Operating Margin
3.1%
Profit Margin
-0.5%
Debt to Equity
0.91
Operating Cash Flow
-$1M
Beta
0.35
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MCTA Overview
Operating through its subsidiaries and under the Beauty Lab brand in Hong Kong, Charming Medical Limited delivers a comprehensive suite of beauty, wellness, and postpartum services. These services encompass womb-warming therapy, BTS (Beauty, Tailor-made, Slim) pelvic detox, agarwood moxibustion, TCM-inspired prenatal massages, and Indonesian traditional abdominal binding. In addition to these treatments, the company manufactures and distributes various products. Their product line features TCM-inspired supplements, including the Beauty Lab home herbal uterine care patch, probiotic intimate wash, and Yin nourishing pill sets. They also offer beauty products like a ginseng soothing anti-allergy moisturizing wash for various skin issues and solutions for scalp health. The company further provides consultancy services, offering technical training in TCM-inspired therapies and dietary guidance to other well-regarded beauty salons, massage centers, and similar institutions. These services and products are specifically formulated to alleviate premenstrual syndrome, menstrual irregularities, dysmenorrhea, leukorrhea, pelvic inflammatory disease, menopausal symptoms, and concerns related to breast and uterine health. They also contribute to enhancing overall physical strength and balancing endocrine functions, addressing a wide array of common women's health challenges. Charming Medical operates its own network of wellness centers. Founded in 2016, the company maintains its headquarters in Causeway Bay, Hong Kong.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MCTA's potential to beat the market
- MCTA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
A
MCTA
RankedUnranked of 40
RankedUnranked of 40
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $268.89 | A | |
| $30.71 | A | |
| $542.18 | A |
Be the first to know about important MCTA news, forecast changes, insider trades & much more!
MCTA News
Overview
Due Diligence Score
–
Industry Average (32)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MCTA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MCTA ($29.36) is overvalued by 1,681.31% relative to our estimate of its Fair Value price of $1.65 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MCTA ($29.36) is not significantly undervalued (1,681.31%) relative to our estimate of its Fair Value price of $1.65 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MCTA was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MCTA due diligence checks available for Premium users.
Valuation
MCTA fair value
Fair Value of MCTA stock based on Discounted Cash Flow (DCF)
Price
$29.36
Fair Value
$1.65
Overvalued by
1,681.62%
MCTA ($29.36) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MCTA ($29.36) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MCTA was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MCTA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
97.33x
Industry
5.86x
MCTA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MCTA's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
MCTA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MCTA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.9M
Liabilities
$4.7M
Debt to equity
0.91
MCTA's short-term assets ($8.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MCTA's short-term assets ($8.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MCTA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
MCTA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MCTA vs Medical Care Facility Stocks
Charming Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.